Ian Ratcliffe
Ian Ratcliffe

Executive Managing Partner
Executive Managing Director

Joined Sands Capital


Work Experience

Sands Capital (2016 - 2022)
Arlington, VA | Managing Partner

Enzymatics Inc. (2013 - 2015)
Beverly, MA | CEO

Stemgent Inc. (2008 - 2013)
Cambridge, MA | Founder, CEO

Upstate Inc. (2002 - 2004)
Charlottesville, VA | President


University of Virginia
MBA | Darden School

University of Surrey
Chemical Engineering

Ian is a serial entrepreneur and has 20 years of experience starting and investing in life sciences technology businesses as an angel, venture and private equity investor. Ian has served in many roles as a founder, CEO, CFO, COO, chairman, director, and advisor to a number of privately-held Life Science product and service businesses. He has focused on the cell signaling, drug screening, genomics and sequencing, and cell culture and modification segments, at all stages of business development from initiation through profitability to trade sell. Prior to joining Sands Capital, Ian was the Chairman and CEO of Enzymatics Inc., founder and CEO of Stemgent, Inc., a stem and iPS cell life sciences tool, and President of Upstate Inc., a leading provider of cell signaling research products and services. Ian was also a founding investor in Firefly Bioworks and Genometry, both SCV investments. Ian has a degree in Chemical Engineering from University of Surrey and has a MBA from the Darden School at the University of Virginia.

Investment Strategy
A Faster-Moving Venture Capital Landscape
Companies often become well established before they go public, and the competition among investors for deals has greatly intensified.
Sands Capital Names Ian Ratcliffe to Executive Management Team
Ian has been instrumental in the development of the venture and private life sciences investing programs. His selection to the leadership team comes as Sands Capital continues to build its private market capabilities.
Sands Capital Closes $560 Million Life Sciences Fund
This is Sands Capital’s second life sciences-dedicated fund, and the team will continue investing with an emphasis on private therapeutics, diagnostics, and life sciences tools businesses.

Let’s Talk